Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
OBJECTIVE
The quality attributes of extemporaneous delayed-release liquid formulations of lansoprazole for oral administration were evaluated.


METHODS
A novel liquid formulation (3 mg/mL) of Prevacid FasTab in an Ora-Blend vehicle was prepared and compared with the Prevacid FasTab 30 mg and Prevacid-sodium bicarbonate 1 M formulation (3 mg/mL). The latter formulation was combined with hydrochloric acid 0.1 N, and the remaining lansoprazole content was assayed by high-performance liquid chromatography (HPLC). A batch of delayed-release liquid formulation was prepared to evaluate content uniformity. For content assay, three samples were prepared for each evaluated condition and each sample was analyzed in triplicate by HPLC.


RESULTS
The lansoprazole in the sodium bicarbonate formulation was extensively degraded by quantities of hydrochloric acid 0.1 N in excess of 100 mL. Storage time and temperature had a significant effect on lansoprazole stability in the Ora-Blend formulation. The drug remained stable for seven days when the formulation was stored at 4.5-5.5 °C, but storage at 21-22 °C or the reduction of pH with citric acid accelerated lansoprazole degradation. The amount of lansoprazole released from the Ora-Blend formulation during the buffer stage of the dissolution test decreased with increases in formulation storage time, in formulation storage temperature, and in the amount of lansoprazole released and degraded during the acid stage of the test.


CONCLUSIONS
An extemporaneous formulation consisting of lansoprazole microgranules in Ora-Blend maintained acceptable quality attributes when stored for three days at 4.5-5.5 °C.
University of Montreal, Canada.
Alexandre
A
Melkoumov
Amina
A
Soukrati
Igor
I
Elkin
Jean-Marc
JM
Forest
Patrice
P
Hildgen
Grégoire
G
Leclair
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000737:chemistry* / Q000592:standards; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004355:Drug Stability; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000737:chemistry* / Q000592:standards; D013535:Suspensions; D013696:Temperature
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D003692:Delayed-Action Preparations; D005079:Excipients; D054328:Proton Pump Inhibitors; D013535:Suspensions; D064747:Lansoprazole